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High prevalence of vertebral
deformities in elderly patients with
early rheumatoid arthritis
Generalised osteoporosis and local bone loss is a well-known
complication of rheumatoid arthritis (RA). Vertebral fractures
are the most common type of osteoporotic fracture and are
associated with increased mortality and morbidity.1 The
presence of vertebral fractures increases the risk of new vertebral
and non-vertebral fractures.2 The prevalence of vertebral
deformities in the Dutch population aged over 55 years in
women and men is 15% and 12%, respectively.3 For patients
with established RA (mean duration 16.6 years), an odds ratio
for vertebral deformities of 2.0 was found,4 leading to an
expected prevalence of vertebral deformities in elderly RA
patients of 30% and 24% for women and men, respectively. As
data on vertebral deformities in early RA are scarce, we
measured the prevalence of this condition in a cross-sectional
study.
Consecutive patients aged over 60 years who fulfilled the
1987 American College of Rheumatology criteria for RA at the
first visit to our early arthritis clinic and completed a minimum
of 2 years follow-up were included. The cumulative disease
activity per patient during follow-up was calculated as the
average disease activity score in 28 joints. Bone mineral density
(BMD) was measured of the total hip and vertebrae L2–L4.
Radiographs of the spine (T5–L4) were performed and scored
according to a standardised semiquantitative method.5 Grades 0
to 3 represent a reduction in anterior, middle and/or posterior
vertebral heights of less than 20%, 20–25%, 25–40% and over
40%, respectively.
Ninety-eight patients (69% women) were included. The mean
age at study inclusion was 68.7 years and the mean duration of
follow-up was 6.1 years. Sixty per cent were anti-cyclic
citrullinated peptide antibody positive. Vitamin D levels of less
than 20 nmol/l were not found. In 28 patients (29%) at least
one vertebral deformity was found (table 1).
The group of patients with versus the group without
vertebral deformities had similar mean cumulative disease
activity scores in 28 joints (3.59 vs 3.57) and health assessement
questionnaire scores (0.63 vs 0.50, both NS). However, they
were older on average (p = 0.001), and had lower mean BMD of
the hip (p = 0.017) compared with those without vertebral
deformities, even a trend remained after correction for age,
Table 1 Comparison of characteristic findings in pansclerotic morphea,
diffuse scleroderma, scleromyxoedema and scleroedema
Pansclerotic
morphea
Diffuse
scleroderma
Sclero-
myxoedema Scleroedema
Face +/2 ++ ++ +/2
Ears 2 + ++ 2
Neck + ++ ++ ++
Chest Tank top Diffuse + 2
Areolae 2 2 2 2
Central back ++ 2 + ++
Arms + ++ + +/2
Legs + ++ + +/2
Feet + ++ 2 +/2
Hands +/2 ++ + 2
Fingers 2 ++ 2 2
Nailfold capillaries Normal Abnormal Normal Normal
Autoantibodies Uncommon Present Uncommon Absent
Monoclonal
gammopathy
Absent Uncommon Present Uncommon
2, not typically involved; +/2, rarely involved; +, often involved; ++, characteristically
involved.
Table 1 Number of vertebral deformities (N = 98)
Vertebral deformities N (%)
No deformity 70
One deformity 21 (21.5)
Grade I 16
Grade II 4
Grade III 1
Two deformities 7 (7.1)
Grade I 2
Grade I + II 2
Grade II 1
Grade II + III 1
Grade III + III 1
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gender and rheumatoid factor status (p = 0.07). The mean BMD
of the spine did not differ between the groups. The mean Z-
scores were lower in those with a vertebral deformity; the
difference was statistically significant at the hips. The use of
corticosteroids, disease-modifying antirheumatic drugs, anti-
tumour necrosis factor or bisphosphonates did not differ
between the groups. Of 28 patients with vertebral deformities,
only eight (29%) used bisphosphonates.
Almost 30% of these elderly patients with relatively early RA
had vertebral deformities, which is in line with the pre-
estimated percentage for patients over 60 years of age with
established RA. This figure is higher than was found in the
healthy population6 and is in line with previous studies in
longstanding RA of more than 15 years’ duration.7 8 The
presently found association between vertebral deformities and
low Z-scores and BMD of the hip is also in accordance with
previous data.7 9 Only a minority of patients received bis-
phosphonate treatment, although bisphosphonates can reduce
vertebral fractures by almost 50%.10
In conclusion, these results support the need for alertness for
vertebral deformities even in early RA.
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Opposite relationships between
circulating Dkk-1 and cartilage
breakdown in patients with
rheumatoid arthritis and knee
osteoarthritis
Recent animal and clinical studies have suggested that Dkk-1, a
secreted inhibitor of the canonical Wnt signalling pathway,
could play an important role in mediating the alterations of
joint tissue turnover associated with rheumatoid arthritis (RA)
and osteoarthritis. Diarra et al1 showed that blockage of Dkk-1
abolished bone erosion in an inflammatory mouse model and
that circulating Dkk-1 was increased in patients with active RA.
More recently, we reported that increased Dkk-1 was associated
with a higher risk of radiological bone erosion in patients with
early RA receiving anti-tumour necrosis factor therapy.2 On the
other hand, elevated circulating levels of Dkk-1 were reported to
be moderately associated with reduced radiological progression
of hip osteoarthritis in one study of elderly women.3 The
relationship between Dkk-1 and cartilage turnover in patients
with RA and osteoarthritis is, however, unknown.
In this study we compared circulating Dkk-1 measured by
ELISA (Biomedica, Vienna, Austria)2 in 55 patients with active
RA (65% women; mean age 55.4 years (SD 14.1), median
disease duration 11 years), 85 subjects with knee osteoarthritis
(74% women; mean age 62.8 years (SD 7.7), radiological
Kellgren–Lawrence score II–III, median disease duration
3.45 years) and 93 healthy sex and age-matched controls and
investigated its association with biochemical markers of
cartilage degradation. All patients met the American College
of Rheumatology criteria.
Circulating Dkk-1 levels were on average 479% higher
(p,0.001) in patients with RA, but 37% (p,0.0001) lower in
subjects with knee osteoarthritis (table 1) compared with
healthy controls (3724 pg/ml; SD 1179). In patients with RA,
Dkk-1 levels were associated with pain (r = 0.40, p,0.001) and
disease activity scores in 28 joints (r = 0.25, p = 0.06), but not
with C-reactive protein levels (p = 0.58) as previously reported.2
Dkk-1 were also positively associated with serum levels of the
type II collagen degradation markers Helix-II (r = 0.49,
p,0.001) and C2C (r = 0.60, p,0.001).4 The 33 (60%) RA
patients with Dkk-1 levels above the 95th percentile of healthy
controls had 38% (p,0.05) higher Helix-II levels than the 21
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